State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018 by Foster, Nicole C. et al.
Title: State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-
2018  
Conscience 
Authors: Nicole C. Foster, MS1, Roy W. Beck, MD, PhD1, Kellee M. Miller, PhD1, Mark A. 
Clements, MD2, Michael R. Rickels, MD, MS3, Linda A. DiMeglio, MD, MPH4, David M. 
Maahs, MD, PhD5, William V. Tamborlane, MD6, Richard Bergenstal, MD7, Elizabeth Smith, 
BS1, Beth A. Olson, BAN, RN, CDE7, Satish K. Garg, MD8 for the T1D Exchange Clinic 
Network 
Author Affiliations: 
1Jaeb Center for Health Research, Tampa, FL 
2Children’s Mercy Hospital, Kansas City, MO 
3University of Pennsylvania Perelman School of Medicine, Rodebaugh Diabetes Center, 
Philadelphia, PA 
4Indiana University School of Medicine, Indianapolis, IN 
5Stanford University, Stanford, CA 
6Yale University School of Medicine, New Haven, CT 
7International Diabetes Center Park Nicollet, Minneapolis, MN 
8University of Colorado Denver, Barbara Davis Center for Childhood Diabetes, Aurora, CO 
Short Running Title: T1D Exchange Registry 2016-2018 
Corresponding Author:  Nicole Foster, Jaeb Center for Health Research, 15310 Amberly 
Drive, Suite 350, Tampa, FL 33647; Phone: (813) 975-8690, Fax: (800) 816-7601, E-mail: 
t1dstats3@jaeb.org  
Portions of this data were presented at the 78th Scientific Session of the American Diabetes 
Association Meeting in Orlando, FL 
Word Count: 2512 
Tables: 2 (total table/figure limit 4) 
Figures: 3 
____________________________________________________
This is the author's manuscript of the article published in final edited form as:
 
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., … Garg, S. K. (2019). State of Type 
1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics, 21(2), 66–
72. https://doi.org/10.1089/dia.2018.0384
Page 2 of 37 
 
Abstract (250/250) 
 
Objective: To provide a snapshot of the profile of adults and youth with type 1 diabetes (T1D) 
in the U.S. and assessment of longitudinal changes in T1D management and clinical outcomes in 
the T1D Exchange registry. 
Research Design and Methods: Data on diabetes management and outcomes from 22,697 
registry participants (age 1-93 years) were collected between 2016 and 2018 and compared with 
data collected in 2010-2012 for 25,529 registry participants.   
Results: Mean HbA1c in 2016-2018 increased from 65 mmol/mol at age 5 years to 78 
mmol/mol between ages 15-18, with a decrease to 64 mmol/mol by age 28 and 58-63 mmol/mol 
beyond age 30.  The American Diabetes Association (ADA) HbA1c goal of <58 mmol/mol for 
youth was achieved by only 17% and the goal of <53 mmol/mol for adults by only 21%.  Mean 
HbA1c levels changed little between 2010-2012 and 2016-2018, except in adolescents who had a 
higher mean HbA1c in 2016-2018.  Insulin pump use increased from 57% in 2010-2012 to 63% 
in 2016-2018.  Continuous glucose monitoring (CGM) increased from 7% in 2010-2012 to 30% 
in 2016-2018, rising >10-fold in children <12 years old. HbA1c levels were lower in CGM users 
than nonusers.  Severe hypoglycemia was most frequent in participants >50 years old and 
diabetic ketoacidosis was most common in adolescents and young adults. Racial differences 
were evident in use of pumps and CGM and HbA1c levels. 
Conclusions: Data from the T1D Exchange registry demonstrate that only a minority of adults 
and youth with T1D in the U.S. achieve ADA goals for HbA1c.   
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In 2010, the T1D Exchange clinic registry initiated the first large database of clinical 
characteristics and clinical outcomes of children and adults with type 1 diabetes throughout the 
U.S. The data have provided an overview of the state of metabolic control, acute complications, 
and diabetes management of type 1 diabetes in the U.S. (1; 2) and the opportunity to compare 
U.S. data with other registries from Europe and Australia (3-12).    
 
Herein, we present an updated snapshot of the state of T1D in the U.S. and an assessment 
of changes over time. 
 
Methods  
The T1D Exchange Clinic Registry data collection was performed by 81 U.S. based 
pediatric and adult endocrinology practices in 35 states. Nineteen and 38 centers primarily care 
for adult and pediatric patients respectively, and 24 care for both. Sixty-three are institution-
based, 17 are community based, and one is in a managed care setting. Details on eligibility 
criteria, the informed consent process, and baseline data collection have been published 
previously (1).  During the initial enrollment period (September 2010 through August 2012), 
25,833 individuals with T1D (14,593 <18 years old and 11,240 ≥18 years old) were enrolled.  
Subsequently, an additional 8,544 participants were enrolled through August, 2017.  Core data 
were updated annually from medical records.  
 
This report includes data from 22,697 participants collected between January 1, 2016 and 
March 31, 2018 (N=3,536 in 2016, N=15,955 in 2017, and N=3,206 in 2018). Participants with a 
Page 4 of 37 
 
history of pancreas or islet cell transplantation and those pregnant at the time of data collection 
were excluded.   
 
Participants who were followed for 5 years completed a detailed questionnaire regarding 
diabetes management and acute complications (Year 5 questionnaire), similar to the 
questionnaire completed at enrollment (N=11,061).   
 
Information on age, date of diagnosis, body mass index (BMI; height and weight), 
insurance status, insulin pump use, continuous glucose monitoring (CGM) use, non-insulin 
glucose-lowering medication use, and HbA1c levels obtained as part of usual care were collected 
from medical records. Frequency of self-monitoring of blood glucose (SMBG) was assessed 
from meter download (if available) or from participant report in the clinic chart. The occurrences 
of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) in the prior 3 months and aspects 
of diabetes management including timing and frequency of insulin administration, duration of 
technology use, use of technology features, use of CGM to decide/adjust insulin dose, checking 
for ketones, use of glucagon, device downloading, and use of mobile medical applications were 
participant-reported from the subset of participants/caregivers who completed the Year 5 
questionnaire. For an event to be counted as SH required loss of consciousness or seizure and for 
an event to be counted as DKA required an overnight hospitalization.    
 
Statistical Methods 
Results were tabulated according to age group.  Cross-sectional comparisons of data 
collected during 2010-2012 were made with data collected during 2016-2018; 12,705 
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participants had information available from both the 2010-2012 and 2016-2018 time periods. 
Cross-sectional comparisons of use of pump and use of CGM included participants with at least 
1 year diabetes duration. To assess mean HbA1c over the lifespan, participants were grouped by 
year of age at the time of measurement. To minimize the impact of potential cohort effects and 
duration effects, cross-sectional comparisons of HbA1c included 9,657 participants contained in 
both time cohorts with at least 3 years of duration at the time of the 2010-2012 data collection. 
 
Multivariable linear regression models were used to assess the association between 
HbA1c and time period (2010-2012 and 2016-2018), and to assess the association between 2016-
2018 HbA1c and participant characteristics adjusting for age, diabetes duration, and clinic site. 
Multivariable logistic regression models were used to assess the association between reported SH 
and DKA (separately) in 2016-2018 and the following: insulin pump use, CGM use, and HbA1c. 
To account for possible confounding, the following covariates were assessed for associations 
with each outcome through bivariate analysis and selection models: age, diabetes duration, 
race/ethnicity, sex, SMBG, insurance status, pump status (when not covariate of interest), CGM 
(when not covariate of interest) status, HbA1c (when not covariate of interest) clinic. 
 
Results are expressed as means ± standard deviations for normally distributed variables 
or medians (interquartile range) for non-normally distributed variables. Data analyses were 
performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC).  All p-values are two-
sided. 
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Results 
The 22,697 participants with data from 2016-2018 ranged in age from 1 to 93 years old; 
duration of diabetes ranged from <1 year to 80 years, 50% were female, 82% were non-Hispanic 
White, and 74% had private health insurance. About half (10,249 [49%]) of participants were 
overweight or obese. Additional participant and clinical characteristics are described, stratified 
by age, in Supplemental Table S1. Participant and clinical characteristics generally were similar 
between the 2010-2012-time cohort and the 2016-2018-time cohort, although, as expected, 
participants in the 2016-2018 cohort were 4-5 years older with about 4-5 years longer diabetes 
duration (Supplemental Table S2).  
 
Utilization of Diabetes Technology and Aspects of Diabetes Management 
Use of an insulin pump increased from 57% in 2010-2012 to 63% in 2016-2018, with the 
largest increases in children (50% to 64% in children <6 years old and 58% to 68% in children 6-
12 years old) (Supplemental Figure S1). More than half of participants using an insulin pump in 
2016-2018 were using a Medtronic pump (53%); 18% were using an Insulet pump, 18% Animas, 
and 12% Tandem. Use of CGM increased from 7% in 2010-2012 to 30% in 2016-2018, with an 
exponential increase in use beginning between years 2013 and 2014 (Figures 1A and 1B).  
Children had a >10-fold increase in CGM use (4% to 51% in children <6 years old and 3% to 
37% in children 6-12 years old) (Figure 1B). Most participants using CGM in 2016-2018 were 
using a Dexcom CGM system (77%). Racial disparities were present in frequency of pump and 
CGM use across all age groups (Supplemental Table S3). 
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Use of non-insulin glucose-lowering medication in addition to insulin was uncommon 
across all age groups (Supplemental Table S1) although use increased slightly between 2010-
2012 and 2016-2018 (Supplemental Table S2). Metformin was the most common non-insulin 
medication but used by only 6% of participants ≥26 years old.   
 
Aspects of diabetes self-management in 2016-2018 are described in Supplemental Table 
S4. Of note, among non-CGM users, SMBG was done more frequently in younger pediatric 
participants. Most participants bolused insulin prior to the start of a meal. Checking of ketones 
was more common in children than adults, and blood ketones were very uncommonly checked 
across all ages; only about 20% reported having a blood ketone meter. Most participants never 
downloaded blood glucose meters, CGM devices, or insulin pumps at home. Other than using the 
Dexcom Share feature by Dexcom CGM users, use of mobile medical applications was very 
uncommon. 
 
Metabolic Control 
2016-2018  
Mean HbA1c levels varied with age, race/ethnicity, and socio-economic status 
(Supplemental Table S5).  Mean HbA1c during childhood increased from 8.1% (65 mmol/mol) 
at 5 years old to 9.3% (78 mmol/mol) between ages 15-18, with a steady decrease down to 8.0% 
(65 mmol/mol) by age 28; mean HbA1c remained fairly steady around 7.5%-7.9% (58-63 
mmol/mol) beyond age 30 (Figure 2). The American Diabetes Association (ADA) HbA1c target 
as of 2018 of <7.5% (<58 mmol/mol) for youth with T1D was achieved by only a small 
percentage of children and adolescents <18 years old (17%); only 21% of adults achieved the 
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ADA goal of <7.5% (<53 mmol/mol). Mean HbA1c was higher in African-Americans than non-
Hispanic Whites or Hispanic Whites across all age groups even after adjusting for differences in 
socioeconomic status (Supplemental Table S5).   
 
Across all age groups, HbA1c was lower in pump and CGM users (P<0.001 adjusted for 
age, diabetes duration, race/ethnicity, annual income, SMBG; Figure 3). Among CGM users, 
differences in HbA1c between pump and MDI users were small, except in adolescents and young 
adults where mean HbA1c was lower in pump users than injection users. 
 
Comparison of 2016-2018 Cohort with 2010-2012 Cohort 
Among the 9,657 participants who had data present in both 2010-2012- and 2016-2018- 
and at least 3 years diabetes duration in 2010-2012, mean HbA1c was higher in 2016-2018 as 
compared with 2010-2012. The adjusted mean HbA1c was 7.8% (62 mmol/mol) in 2010-2012 
and 8.4% (68 mmol/mol) in 2016-2018 (P<0.001 adjusted for age, diabetes duration, SMBG, and 
use of a CGM). The increase over time in HbA1c was predominately seen in adolescents and 
young adults (Figure 2).  
 
Acute Complications in 2016-2018 Cohort 
Among the subset of participants with data available from the Year 5 questionnaire 
(N=11,061), 6% reported experiencing seizure or loss of consciousness due to hypoglycemia in 
the 3 months prior to questionnaire completion; 3-month frequency of SH (seizure/LOC) ranged 
from 5% in participants <18 years old to 10% in participants ≥50 years old (Table 1). Insulin 
pump use was associated with lower frequency of experiencing a SH event (5% versus 9%; 
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P<0.001 adjusted for age, diabetes duration, sex, race/ethnicity, insurance status, CGM status) 
and CGM use trended towards a lower SH frequency (5% versus 7%; P=0.06 adjusted for age, 
diabetes duration, sex, race/ethnicity, insurance status, and pump use). The frequency of SH was 
not associated with HbA1c level (P=0.55 adjusted for age, diabetes duration, sex, race/ethnicity, 
insurance status, CGM use, pump use; Table 1). 
   
At least one DKA event in the 3 months prior to the questionnaire was reported by 3% of 
participants, with the highest frequency (4%) in participants <26 years old (Table 1).  
Participants using an insulin pump were less likely to report experiencing a DKA event than 
participants using injections (2% versus 4%; P=0.002 adjusted for age, diabetes duration, sex, 
race/ethnicity, insurance status, CGM, SMBG, and HbA1c). Similarly, participants using CGM 
had fewer DKA events than non-CGM users (1% versus 3%; P=0.04 adjusted for age, diabetes 
duration, sex, race/ethnicity, insurance status, pump use, and HbA1c). Participants with higher 
HbA1c were more likely to experience a DKA event than participants with lower HbA1c (0.7% 
in participants with HbA1c <8.0% [<64 mmol/mol] and 7% in participants with HbA1c ≥9.0% 
[≥75 mmol/mol]; P<0.001 adjusted for age, diabetes duration, sex, race/ethnicity, insurance 
status, SMBG, CGM status, pump status). 
 
Discussion 
The T1D Exchange registry has provided important information about individuals with 
type 1 diabetes, how type 1 diabetes is managed in the US along with clinical outcomes. In the 
most recent data reported herein, across all age groups only a minority of individuals meet ADA 
HbA1c goals and HbA1c levels remain particularly high in adolescents and young adults. 
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Indeed, mean HbA1c levels have increased from 2010-2012 to 2016-2018 in teens and emerging 
adults. This surprising finding remained after limiting the analysis to the participants who had 
T1D duration of at least 3 years at baseline (2010-2012) and after adjustment for age and 
duration of diabetes. Within this age range of adolescents and young adults, factors that have 
been associated with HbA1c levels such as race/ethnicity and socio-economic status appeared 
balanced between the two time periods (data not shown). Thus, we do not have an explanation 
for this increase and it is possible that the finding could reflect a difference in diabetes duration 
between time periods even though duration was adjusted for in analysis or be due to other 
unmeasured confounding factors. Nevertheless, there is no indication from these data that HbA1c 
levels in the registry as a whole have improved over this 5-year period despite an increase in the 
use of insulin pumps and CGM. 
 
HbA1c levels were higher in African Americans than in non-Hispanic or Hispanic whites 
as previously reported in the registry (13).  A T1D Exchange study demonstrated that only about 
half of the HbA1c difference between whites and African-Americans can be explained by higher 
mean glucose in African-Americans, with the other half of the difference between races having a 
non-glycemic basis presumably due to genetic differences in red blood cell lifespan, differences 
in red blood cell glycation rates, or other, as of yet undefined, biologic or genetic factors (14).  
Of interest, a difference in HbA1c levels between race/ethnicities exists even among those in the 
highest income category.   
 
As shown previously, SH occurs more commonly in older adults than in younger 
participants particularly those with long duration of type 1 diabetes. A prior T1D Exchange study 
Page 11 of 37 
 
demonstrated that hypoglycemia unawareness is a substantial risk factor for SH in older adults 
(15).   In an attempt to standardize self-reporting of SH in a large registry, SH was defined by the 
occurrence of seizure or loss of consciousness.  Of note, SH risk was not associated with HbA1c 
level in contrast to the Diabetes Control and Complications Trial which found a strong 
association of lower HbA1c levels with a higher SH risk (16). However, the risk of DKA was 
strongly associated with HbA1c levels, with a substantial increase in DKA risk at HbA1c levels 
>9.0% (>75 mmol/mol) presumably representing more frequent missed insulin doses. As seen 
previously, DKA risk was highest in adolescents and young adults. 
 
Perhaps the most notable change in diabetes management over the 5-7 years of registry 
data is the substantial increase in use of CGM in recent years. This increase has been most 
prominent in young children, presumably related to the ability of a parent to monitor the CGM 
glucose data remotely. It is noteworthy that there has been minimal adoption of other mobile 
medical applications. Pump use has increased modestly over this time period. The benefit of 
pump use and CGM use on HbA1c levels is apparent across age groups. Among CGM users, 
HbA1c levels were similar whether the participants were using MDI or an insulin pump, 
supporting the finding of clinical trials that have demonstrated benefit of CGM in MDI users to 
be comparable to that demonstrated in pump users (17; 18). Pump use was associated with a 
lower DKA frequency compared with injection users. Although this is likely related to 
differences between pump users and MDI users rather than the insulin delivery modality, this 
finding nevertheless shows no indication that pump use poses an increased DKA risk. This 
finding is consistent with that of the DPV registry (19). Pump users also had a lower SH 
frequency than MDI users. Although CGM users would be expected to have a lower SH 
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frequency than nonusers, the difference was relatively small, which could be reflecting the 
possibility that CGM was prescribed because of frequent SH. SH and DKA events were 
collected using different criteria in 2010-2012 precluding a comparison with the data from the 
earlier period.  Although use of devices has increased, downloading of device data with 
retrospective review of the data as part of diabetes self-management has not.  With recent greater 
emphasis on seamless transmission of data to the cloud and enhancements in reporting and 
decision-support tools, the integration of device data into self-management can be expected to 
increase. 
 
Despite the value of the data from the registry, there are limitations to the interpretation 
of the results. The registry is not population-based as all participants in the registry are treated at 
endocrinology centers that focus on the care of patients with type 1 diabetes, nor are all patients 
at each clinic included in the registry. Thus, individuals not being seen by an endocrinologist are 
not represented and underinsured/uninsured individuals are likely underrepresented as well. As a 
result, certain reported frequencies such as use of devices likely are overestimates. The low 
proportion of registry participants meeting ADA HbA1c targets, particularly in adolescents and 
young adults, also is more likely to be an overestimate than underestimate, indicating that 
glycemic control in a general population of youth and adults with type 1 diabetes may be even 
worse than what was found in the registry. 
 
In summary, recent data from the T1D Exchange registry demonstrate that only a 
minority of adults and youth with T1D meet ADA goals for HbA1c. Glycemic control has not 
improved overall between 2010-2012 and 2016-2018 and in fact appears to have worsened 
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particularly in adolescents. CGM use has substantially increased in recent years and CGM use is 
associated with lower HbA1c levels. Racial disparities remain in use of technology and in 
glycemic control.  We hope that these data will stimulate further research and efforts to find 
ways to improve glucose control and bridge the gap in different racial backgrounds. 
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Table 1. Frequency of Acute Complications in 2016-2018   
 6 - 12 yrs old 13 - 17 yrs old 18 - 25 yrs old 26 - 49 yrs old ≥50  yrs old 
 N # ≥ 1  
Event (%) 
N # ≥ 1  
Event (%) 
N # ≥ 1  
Event (%) 
N # ≥ 1  
Event (%) 
N # ≥ 1  
Event (%) 
Frequency of 1 > Severe Hypoglycemia Event in Prior 3 Months 
Overall 1313 62 (5%) 3183 155 (5%) 2445 138 (6%) 2143 157 (7%) 1976 189 (10%) 
Insulin Delivery Method           
Pump 973 39 (4%) 2134 67 (3%) 1585 78 (5%) 1442 85 (6%) 1243 114 (9%) 
Injections  317 22 (7%) 967 83 (9%) 817 58 (7%) 656 71 (11%) 706 74 (11%) 
CGM Status           
      CGM user 414 14 (3%) 584 15 (3%) 424 17 (4%) 684 36 (5%) 577 39 (7%) 
      CGM non-user 899 48 (5%) 2599 140 (5%) 2021 121 (6%) 1459 121 (8%) 1399 150 (11%) 
Most Recent HbA1c           
<7.0% (<53 mmol/mol)  96 4 (4%) 174 8 (5%) 257 11 (4%) 575 37 (6%) 498 51 (10%) 
7.0-<7.5% (53-<58 mmol/mol) 148 4 (3%) 268 9 (3%) 283 10 (4%) 395 19 (5%) 372 41 (11%) 
7.5-<8.0% (58-<64 mmol/mol) 214 9 (4%) 410 15 (4%) 341 14 (4%) 357 24 (7%) 375 30 (8%) 
8.0-<9.0% (64-<75 mmol/mol) 420 19 (5%) 866 38 (4%) 596 36 (6%) 398 27 (7%) 397 35 (9%) 
≥9.0% (≥75 mmol/mol)  380 25 (7%) 1370 79 (6%) 888 60 (7%) 265 36 (14%) 184 17 (9%) 
Frequency of >1 Diabetic Ketoacidosis Event in Prior 3 Months 
Overall 1313 31 (2%) 3183 113 (4%) 2445 96 (4%) 2143 43 (2%) 1976 22 (1%) 
Insulin Delivery Method           
Pump 973 12 (1%) 2134 49 (2%) 1585 44 (3%) 1442 24 (2%) 1243 14 (1%) 
Injections  317 17 (5%) 967 61 (6%) 817 51 (6%) 656 17 (3%) 706 8 (1%) 
CGM Status           
      CGM user 414 4 (1%) 584 9 (2%) 424 9 (2%) 684 5 (1%) 577 1 (<1%) 
      CGM non-user 899 27 (3%) 2599 104 (4%) 2021 87 (4%) 1459 38 (3%) 1399 21 (2%) 
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Most Recent HbA1c            
<7.0% (<53 mmol/mol)  96 0 174 1 (1%) 257 2 (1%) 575 2 (<1%) 498 3 (1%) 
7.0-<7.5% (53-<58 mmol/mol) 148 1 (1%) 268 3 (1%) 283 3 (1%) 395 2 (1%) 372 2 (1%) 
7.5-<8.0% (58-<64 mmol/mol) 214 3 (1%) 410 2 (1%) 341 5 (1%) 357 2 (1%) 375 0 
8.0-<9.0% (64-<75 mmol/mol) 420 5 (1%) 866 18 (2%) 596 9 (2%) 398 9 (2%) 397 8 (2%) 
≥9.0% (≥75 mmol/mol)  380 20 (5%) 1370 83 (6%) 888 74 (8%) 265 25 (9%) 184 5 (3%) 
 
  
Page 17 of 37 
 
Figure 1A. Continuous Glucose Monitoring Use over Time 
 
 
Figure 1B. Continuous Glucose Monitoring Use 2010-2012 versus 2016-2018 
 
 
Figure Legend 
Solid white represents 2010-2012 (7% use CGM overall) 
Solid black represents 2016-2018 (30% use CGM overall) 
 
  
Page 18 of 37 
 
Figure 2. Average HbA1c by Year of Age: 2010-2012 versus 2016-2018 
 
 
Orange line represents 2010-2012 cohort, blue line represents 2016-2018 cohort 
Participants must be contained in both cohorts with at least 3 years duration for the 2010-2012 collection 
*>80 years old are pooled  
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Figure 3. Mean HbA1c by Technology Use in 2016-2018 
 
Figure Legend 
Solid black represents Injection only. 
Horizontal stripes represent Pump only. 
Solid white represents Injection+CGM. 
Diagonal stripes represent Pump+CGM. 
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Supplemental Table S1. Participant Characteristics: 2016-2018 
 Overall 1 - 5       
yrs old 
6 - 12  
yrs old 
13 - 17  
yrs old 
18 - 25  
yrs old 
26 - 49  
yrs old 
≥50     
 yrs old 
 N=22,697 N= 415 N=3688 N= 6675 N= 4535 N= 3939 N=3445 
Demographic and Clinical Characteristics        
Sexa – N(%) Female 11,394 (50%) 185 (45%) 1772 (48%) 3249 (49%) 2235 (49%) 2143 (55%) 1810 (53%) 
Race/Ethnicitya- N(%)         
     White Non-Hispanic 18,368 (82%) 317 (78%) 2775 (76%) 5142 (77%) 3606 (80%) 3353 (86%) 3175 (93%) 
     Black Non-Hispanic 1288 (6%) 22 (5%) 251 (7%) 436 (7%) 224 (5%) 217 (6%) 138 (4%) 
     Hispanic or Latino 1866 (8%) 42 (10%) 382 (11%) 703 (11%) 495 (11%) 193 (5%) 51 (1%) 
     Other 1008 (4%) 26 (6%) 228 (6%) 365 (5%) 199 (4%) 134 (3%) 56 (2%) 
Annual Household Incomea- N(%)        
     < $50,000 5086 (31%) 110 (36%) 949 (34%) 1564 (31%) 879 (29%) 953 (31%) 631 (25%) 
     $50,000 - <$75,000 2817 (17%) 59 (19%) 471 (17%) 829 (17%) 441 (15%) 552 (18%) 465 (19%) 
     ≥$75,000 8725 (52%) 134 (44%) 1357 (49%) 2580 (52%) 1703 (56%) 1535 (50%) 1416 (56%) 
Education Levela – N(%)        
Less than Bachelor degree 10,558 (49%) 221 (55%) 1760 (50%) 3192 (50%) 2427 (57%) 1554 (43%) 1404 (45%) 
Bachelor degree  6049 (28%) 97 (24%) 940 (27%) 1735 (27%) 980 (23%) 1374 (38%) 923 (30%) 
Master, professional or doctorate 4724 (22%) 86 (21%) 811 (23%) 1435 (23%) 881 (21%) 715 (20%) 796 (25%) 
Insurance Statusa – N(%)        
Private 16,028 (74%) 242 (63%) 2324 (68%) 4503 (72%) 3498 (80%) 3229 (85%) 2232 (66%) 
Other 5339 (25%) 139 (36%) 1032 (30%) 1716 (27%) 812 (19%) 517 (14%) 1123 (33%) 
None 243 (1%) 5 (1%) 49 (1%) 68 (1%) 48 (1%) 50 (1%) 23 (<1%) 
Duration of Diabetes  - median (IQR) 10 (6, 19) 2 (2, 3) 6 (3, 7) 8 (6, 11) 11 (8, 15) 22 (15, 29) 35 (23, 46) 
Duration Group- N(%)        
1-< 5 years 3392 (15%) 370 
(>99%) 
1509 (42%) 1113 (17%) 261 (6%) 99 (3%) 40 (1%) 
5-< 10 years 7300 (32%) 2 (<1%) 1949 (54%) 3313 (50%) 1527 (34%) 378 (10%) 131 (4%) 
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10-<20 years 6617 (29%) - 159 (4%) 2190 (33%) 2551 (56%) 1211 (31%) 506 (15%) 
20-< 30 years 2207 (10%) - - - 186 (4%) 1372 (35%) 649 (19%) 
30-< 40 years 1489 (7%) - - - - 718 (18%) 771 (22%) 
40-< 49 years 985 (4%) - - - - 153 (4%) 832 (24%) 
≥ 50 years 516 (2%) - - - - - 516 (15%) 
BMI Z-Scorea- mean ± SD 0.4±1.0 0.8±1.1 0.6±1.2 0.8±1.0 0.2±1.0 0.09±0.8 -0.1±0.8 
BMI Groupb - N(%)        
Underweight/Normal Weight  10,577 (51%) 239 (59%) 2457 (67%) 3793 (58%) 2183 (52%) 1002 (31%) 903 (33%) 
Overweight  6022 (29%) 98 (24%) 728 (20%) 1651 (25%) 1334 (32%) 1169 (36%) 1042 (38%) 
Obese  4227 (20%) 68 (17%) 466 (13%) 1122 (17%) 679 (16%) 1074 (33%) 818 (30%) 
        
Diabetes Management        
Pump usea – N (%) 14,047 (63%) 233 (64%) 2403 (68%) 4040 (62%) 2700 (60%) 2542 (66%) 2129 (62%) 
CGM usea – N(%) 6547 (30%) 183 (51%) 1302 (37%) 1553 (24%) 963 (22%) 1402 (37%) 1144 (34%) 
Self-Monitoring of Blood Glucosec- mean ± 
SD 
4.1±2.4 6.4±2.4 5.5±2.3 3.8±2.2 3.3±2.4 3.9±2.4 4.6±2.3 
0-3 times per day 5402 (41%) 10 (6%) 295 (14%) 2062 (46%) 1641 (58%) 885 (45%) 509 (28%) 
4-6 times per day 5947 (45%) 85 (53%) 1139 (56%) 1912 (43%) 946 (33%) 861 (44%) 1004 (55%) 
6-9  times per day 1508 (11%) 48 (30%) 482 (24%) 384 (9%) 184 (6%) 163 (8%) 247 (13%) 
≥ 10 times per day 448 (3%) 17 (11%) 133 (6%) 91 (2%) 66 (2%) 66 (3%) 75 (4%) 
Non-insulin medications for blood glucose 
control- N(%) 
       
Metformin 811 (4%) 0 12 (<1%) 185 (3%) 171 (4%) 257 (7%) 186 (5%) 
GLP-1 agonist 300 (1%) 0 0 8 (<1%) 27 (<1%) 163 (4%) 102 (3%) 
DPP-IVi 9 (<1%) 0 0 0 0 4 (<1%) 5 (<1%) 
SGLT2i 232 (1%) 0 0 1 (<1%) 14 (<1%) 119 (3%) 98 (3%) 
Pramlintide 131 (>1%) 0 0 3 (<1%) 9 (<1%) 52 (1%) 67 (2%) 
Otherd 28 (<1%) 0 0 2 (<1%) 2 (<1%) 10 (<1%) 14 (<1%) 
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a39 transgender participants; race/ethnicity information missing for 167 participants; Annual income missing for 6069 participants; education information missing for 1366 
participants; insurance status information missing for 1087 participants; BMI information missing for 1872 participants; insulin modality (pump use) information missing for 528 
participants; information on use of CGM missing for 899 participants| parental education level used for participants <18 years old 
b Underweight/Normal weight defined as  < 85th bmi percentile adjusted for age and sex for participants < 20 years and bmi < 25 for adults ≥ 20 years, overweight defined as 85th - 
< 95th bmi percentile for participants < 20 years and bmi 25-<30 for adults ≥ 20 years , obese defined as ≥ 95th bmi percentile for participants < 20 years and bmi ≥ 30 for adults ≥ 
20 years; age and sex-adjusted 
csSMBG available for 13,344 participants not using a continuous glucose monitor  
dIncludes: thiazolidinediones and sulfonylureas 
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Supplemental Table S2. Participant Characteristics 2010-2012 versus 2016-2018 
 2010-2012 
N=25,529 
2016-2018a 
N=22,697 
Age (years) - mean±StD 22 ± 17 26 ± 18 
Female – N(%) 12,706 (50%) 11,394 (50%) 
Non-Hispanic White – N(%) 20,954 (82%) 18,368 (82%) 
Private insurance – N(%) 17,081 (75%) 16,028 (74%) 
Duration of diabetes – median (IQR) 6 (2,14) 10 (6, 19) 
BMI z-score - mean±StD 0.4 ± 1.0 0.4 ± 1.0 
Pump use – N(%) 12,637 (57%) 14,047 (63%) 
CGM use – N(%) 1591 (7%) 6547 (30%) 
Self-monitoring of blood glucoseb - 
mean±StD 
4·7 ± 3·0 4·1 ± 2·4 
Non-insulin medications for blood 
glucose control- N(%) 
  
Metformin 388 (2%) 811 (4%) 
GLP-1 agonist 34 (<1%) 300 (1%) 
DPP-IVi 9 (<1%) 9 (<1%) 
SGLT2i 0 232 (1%) 
Pramlintide 124 (<1%) 131 (<1%) 
Otherc 24 (<1%) 28 (<1%) 
StD = standard deviation 
a12,705 (56%) participants in the 2016-2018 cohort also in the 2010-2012 cohort 
bCalculation excludes participants using CGM  
cIncludes: thiazolidinediones and sulfonylureas
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Supplemental Table S3. Use of Technology by Race/Ethnicity: 2016-2018 
 Age (years)  
<13 13 - 25 >26 
White Non-
Hispanic 
Black Non-
Hispanic 
Hispanic or 
Latino 
White Non-
Hispanic 
Black Non-
Hispanic 
Hispanic or 
Latino 
White Non-
Hispanic 
Black Non-
Hispanic 
Hispanic or 
Latino 
Pump use – n(%)          
Annual Household Income          
<$50,000 398 (59%) 37 (37%) 69 (45%) 782 (50%) 65 (25%) 67 (45%) 789 (62%) 40 (29%) 46 (49%) 
$50,000-<$75,000 294 (72%) 9 (41%) 34 (68%) 696 (68%) 16 (28%) 31 (50%) 600 (65%) 21 (51%) 17 (68%) 
>$75,000  1011 (81%) 22 (73%) 62 (72%) 2724 (74%) 47 (52%) 128 (72%) 1902 (70%) 39 (64%) 50 (76%) 
CGM use – n(%)          
Annual Household Income          
<$50,000 172 (26%) 8 (8%) 21 (14%) 227 (15%) 14 (5%) 43 (10%) 312 (25%) 13 (10%) 15 (16%) 
$50,000-<$75,000 172 (43%) 3 (15%) 18 (36%) 225 (22%) 3 (5%) 17 (17%) 315 (35%) 10 (26%) 11 (44%) 
>$75,000 658 (54%) 8 (26%) 46 (55%) 1207 (33%) 8 (9%) 72 (31%) 1218 (46%) 15 (26%) 33 (51%) 
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Supplemental Figure S1. Pump Use 2010-2012 versus 2016-2018 
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Supplemental Table S4. Aspects of Self-Reported Diabetes Management in 2016-2018 
 Overall 6 - 12  
yrs old 
13 - 17  
yrs old 
18 - 25  
yrs old 
26 - 49  
yrs old 
≥50     
 yrs old 
 N=11,007 N=1312 N= 3179 N= 2440 N= 2122 N=1953 
Insulin Use             
Timing of insulin bolus – N(%)             
At least several minutes before the meal 2671 24% 359 27% 626 20% 419 17% 544 26% 723 37% 
Immediately before the meal 4822 44% 579 44% 1491 47% 1009 41% 944 44% 798 41% 
During the meal 1178 11% 105 8% 351 11% 339 14% 262 12% 121 6% 
After the meal 2336 21% 269 21% 711 22% 673 28% 372 18% 311 16% 
Frequency of use of insulin pump features 
to decide insulin dose based on 
carbohydrate intake – N(%) 
            
Always 4892 65% 699 70% 1462 66% 1063 66% 859 59% 809 64% 
Sometimes 1151 15% 100 10% 240 11% 257 16% 326 22% 228 18% 
Rarely 441 6% 32 3% 102 5% 96 6% 141 10% 70 6% 
Never 1084 14% 166 17% 415 19% 197 12% 141 10% 165 13% 
Frequency of use of insulin pump features 
to decide insulin dose based on elevated 
glucose values – N(%) 
            
Always 4984 66% 675 68% 1476 67% 1095 68% 892 61% 846 67% 
Sometimes 1384 18% 149 15% 311 14% 285 18% 383 26% 256 20% 
Rarely 302 4% 25 3% 71 3% 77 5% 80 5% 49 4% 
Never 898 12% 148 15% 361 16% 156 10% 112 8% 121 10% 
Frequency of use of insulin pump features 
to decide insulin dose based on both 
carbohydrate intake and elevated glucose 
values – N(%) 
            
Always 5049 67% 718 72% 1507 68% 1093 68% 864 59% 867 68% 
Sometimes 889 12% 133 13% 344 16% 160 10% 130 9% 122 10% 
Rarely 322 4% 31 3% 74 3% 67 4% 102 7% 48 4% 
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Never 1308 17% 115 12% 294 13% 293 18% 371 25% 235 18% 
Frequency of missed insulin bolus - N(%)             
Never 3330 30% 541 41% 810 25% 535 22% 670 32% 774 40% 
Once a month or less 3411 31% 430 33% 894 28% 687 28% 736 35% 664 34% 
Once a week or less 1867 17% 165 13% 595 19% 501 21% 339 16% 267 14% 
2 days per week 1335 12% 112 9% 482 15% 376 15% 225 11% 140 7% 
3-4 days per week 572 5% 28 2% 208 7% 191 8% 88 4% 56 3% 
5-6 days per week 143 1% 10 <1% 53 2% 41 2% 20 <1% 19 <1% 
At least once a day 351 3% 24 2% 138 4% 112 5% 47 2% 30 2% 
Frequency of missed basal for injection 
usersa – N(%) 
            
Never 2125 61% 248 79% 575 60% 397 48% 417 62% 487 70% 
Once a month or less 911 26% 53 17% 240 25% 265 32% 187 28% 166 24% 
Once a week or less 214 6% 8 3% 65 7% 77 9% 34 5% 30 4% 
2 days per week 119 3% 2 <1% 52 5% 46 6% 15 2% 4 <1% 
3-4 days per week 37 1% 0 0 7 <1% 18 2% 7 1% 5 <1% 
5-6 days per week 7 <1% 2 <1% 2 <1% 2 <1% 1 <1% 0 0 
At least once a day 67 2% 2 <1% 22 2% 27 3% 8 1% 8 1% 
Duration of infusion set wear (days) – 
mean±std 
3.1±0.8 2.8±0.6 2.9±0.7 3.2±0.8 3.4±0.9 3.3±0.9 
Glucose Monitoring             
Frequency of deciding amount of insulin 
bolus based only on CGMb – N(%) 
            
Always 277 7% 22 4% 52 6% 48 7% 99 10% 56 8% 
Most of the time 1154 30% 114 21% 217 24% 232 35% 374 39% 217 29% 
Sometimes 1201 31% 187 34% 306 34% 206 31% 278 29% 224 30% 
Rarely 671 18% 116 21% 177 19% 113 17% 130 14% 135 18% 
Never 510 13% 112 20% 156 17% 58 9% 70 7% 114 15% 
Adjust insulin dose based on trend arrows 
on CGMb – N(%) 2870 75% 400 72% 634 70% 533 81% 773 81% 530 71% 
Ketone Monitoring             
Method of ketone checking – N(%)             
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Blood 943 9% 273 21% 368 12% 194 8% 54 3% 54 3% 
Urine 5233 47% 809 62% 2090 66% 1383 57% 575 27% 376 19% 
Sometimes blood and sometimes urine 333 3% 59 4% 144 5% 89 4% 23 1% 18 <1% 
Rarely check for ketones with blood or urine 1724 16% 119 9% 366 11% 415 17% 443 21% 380 19% 
Never check for ketones 2828 26% 53 4% 215 7% 364 15% 1048 49% 1148 58% 
Has a blood-ketone meter at home – N(%) 2230 20% 490 37% 840 26% 605 25% 173 8% 122 6% 
Has urine ketone strips at home – N(%) 7838 71% 1116 85% 2809 88% 2084 85% 1069 50% 759 38% 
Frequency of checking ketones via blood 
in 30 day period (days)  - median (IQR) 
0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 
Frequency of checking ketones via urine 
in 30 day period (days) – median (IQR) 
0 (0,1) 0 (0,3) 0 (0,2) 0 (0,1) 0 (0,0) 0 (0,0) 
HbA1c Goals       
Participant reported having an HbA1c 
goal – N(%) 10046 91% 1185 90% 2829 89% 2223 91% 2000 93% 1808 91% 
HbA1c goal – N(%)             
<42 mmol/mol (<6%)  670 7% 40 3% 91 3% 107 5% 245 12% 187 10% 
<48 mmol/mol (<6·5%)  1387 14% 85 7% 189 7% 260 12% 490 25% 363 20% 
<53 mmol/mol (<7·0%)  3949 39% 393 33% 958 34% 896 40% 894 45% 808 45% 
<58 mmol/mol (<7·5%)  2391 24% 427 36% 862 31% 563 25% 234 12% 305 17% 
<64 mmol/mol (<8·0%)  1087 11% 189 16% 442 16% 252 11% 100 5% 104 6% 
<69 mmol/mol (<8·5%)  404 4% 38 3% 203 7% 107 5% 27 1% 28 2% 
≥69 mmol/mol (≥8·5%)  112 1% 6 <1% 60 2% 34 2% 6 <1% 6 <1% 
Use of Glucagon             
Used glucagon in prior 3 months to treat 
severe hypoglycemia – N(%) 331 3% 30 2% 81 3% 52 2% 53 2% 115 6% 
Used glucagon in small doses in prior 3 
months before or during exercise – N(%) 
36 <1% 3 <1% 18 <1% 7 <1% 4 <1% 4 <1% 
Used glucagon in small doses in prior 3 
months in place of carbohydrates – N(%) 
29 <1% 8 <1% 9 <1% 6 <1% 2 <1% 4 <1% 
Device Downloading             
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Frequency download blood glucose meter 
outside of doctor’s office: non-CGM 
usersbc – N(%) 
            
Never 5750 71% 529 62% 1590 63% 1420 72% 1115 78% 1095 81% 
<1 time a year 461 6% 53 6% 137 5% 145 7% 84 6% 42 3% 
Once per year 246 3% 34 4% 79 3% 74 4% 37 3% 22 2% 
A few times a year 877 11% 134 16% 337 13% 196 10% 107 7% 103 8% 
Once per month 446 5% 57 7% 207 8% 85 4% 47 3% 50 4% 
2-3 times per month 174 2% 28 3% 85 3% 28 1% 17 1% 16 1% 
Once per week 105 1% 14 2% 43 2% 16 <1% 16 1% 16 1% 
2-5 times per week 26 <1% 4 <1% 14 <1% 2 <1% 4 <1% 2 <1% 
6-7 times per week 47 <1% 5 <1% 19 <1% 8 <1% 6 <1% 9 <1% 
Frequency download blood glucose meter 
outside of doctor’s office: CGM usersbc – 
N(%) 
            
Never 1585 60% 205 51% 289 51% 246 59% 464 69% 381 67% 
<1 time a year 172 7% 18 5% 41 7% 36 9% 45 7% 32 6% 
Once per year 95 4% 14 4% 24 4% 25 6% 15 2% 17 3% 
A few times a year 420 16% 82 21% 114 20% 69 17% 88 13% 67 12% 
Once per month 217 8% 47 12% 63 11% 28 7% 40 6% 39 7% 
2-3 times per month 85 3% 21 5% 22 4% 10 2% 13 2% 19 3% 
Once per week 40 2% 9 2% 15 3% 2 <1% 5 <1% 9 2% 
2-5 times per week 6 <1% 0 0 3 <1% 1 <1% 1 <1% 1 <1% 
6-7 times per week 12 <1% 4 1% 0 0 0 0 5 <1% 3 <1% 
Reason for infrequent meter downloading 
(< once per month)d – N(%) 
            
Do not own computer 564 6% 99 9% 143 5% 106 5% 106 5% 110 6% 
Did not know it was possible to download 1127 12% 98 9% 365 14% 277 13% 198 10% 189 11% 
Did not know how to download 2097 22% 187 17% 536 21% 474 21% 381 19% 519 30% 
Download too hard to understand 444 5% 53 5% 148 6% 67 3% 79 4% 97 6% 
Takes too much time 2133 22% 187 17% 531 20% 566 26% 566 26% 283 16% 
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Meter software not compatible with 
computer 891 9% 117 11% 254 10% 214 10% 153 8% 153 9% 
Get blood glucose downloads from pump 1784 19% 230 22% 516 20% 406 18% 347 18% 285 16% 
Prefer written records 1236 13% 173 16% 360 14% 259 12% 187 10% 257 15% 
Do not find data useful 856 9% 53 5% 174 7% 244 11% 222 11% 163 9% 
Frequency of downloading CGM data 
outside doctor’s officeb – N(%) 
            
Never 2278 51% 262 42% 571 50% 421 51% 552 52% 472 57% 
<1 time per year 280 6% 33 5% 64 6% 62 8% 76 7% 45 5% 
Once per year 144 3% 14 2% 30 3% 34 4% 43 4% 23 3% 
A few times a year 670 15% 126 20% 169 15% 119 15% 161 15% 95 11% 
Once per month 576 13% 100 16% 157 14% 96 12% 127 12% 96 12% 
2-3 times per month 221 5% 43 7% 50 4% 37 5% 48 5% 43 5% 
Once per week 153 3% 27 4% 54 5% 15 2% 25 2% 32 4% 
More than once per week 38 <1% 8 1% 12 1% 6 <1% 8 <1% 4 <1% 
Everyday 125 3% 18 3% 37 3% 29 4% 22 2% 19 2% 
Reason for infrequent CGM downloading 
(<once per month)d – N(%) 
            
Does not own computer 169 5% 26 6% 46 6% 24 4% 39 5% 34 5% 
Did not know it was possible to download 388 12% 49 11% 134 16% 82 13% 60 7% 63 10% 
Did not know how to download 790 23% 102 23% 218 26% 138 22% 158 19% 174 27% 
Download too hard to understand 233 7% 32 7% 58 7% 35 6% 54 6% 54 9% 
Takes too much time 1139 34% 129 30% 241 29% 232 36% 366 44% 171 27% 
CGM software not compatible with 
computer 360 11% 37 9% 59 7% 77 12% 101 12% 86 14% 
Prefer written records 351 10% 67 15% 98 12% 68 11% 53 6% 65 10% 
Does not find data useful 323 10% 25 6% 69 8% 66 10% 91 11% 72 11% 
Frequency download insulin pump data 
outside doctor’s officea – N(%) 
            
Never 4587 60% 456 45% 1148 50% 1054 64% 1017 69% 912 71% 
<1 time per year 503 7% 62 6% 162 7% 134 8% 94 6% 51 4% 
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Once per year 273 4% 40 4% 83 4% 70 4% 45 3% 35 3% 
A few times a year 1173 15% 228 23% 418 18% 213 13% 173 12% 141 11% 
Once per month 756 10% 134 13% 310 14% 130 8% 94 6% 88 7% 
2-3 times per month 251 3% 55 5% 108 5% 29 2% 28 2% 31 2% 
Once per week 120 2% 21 2% 54 2% 6 <1% 20 1% 19 1% 
More than once per week 15 <1% 2 <1% 6 <1% 3 <1% 3 <1% 1 <1% 
Everyday 24 <1% 6 <1% 6 <1% 3 <1% 4 <1% 5 <1% 
Reason for infrequent insulin pump 
downloading (<once per month)d – N(%) 
            
Does not own computer 356 5% 69 9% 95 5% 58 4% 66 5% 68 6% 
Did not know it was possible to download 571 9% 43 5% 169 9% 142 10% 102 8% 115 10% 
Did not know how to download 1584 24% 155 20% 432 24% 322 22% 295 22% 380 33% 
Download too hard to understand 441 7% 61 8% 146 8% 73 5% 76 6% 85 7% 
Takes too much time 2170 33% 226 29% 607 34% 542 37% 535 40% 260 23% 
Insulin pump software not compatible with 
computer 771 12% 117 15% 201 11% 185 13% 143 11% 125 11% 
Prefer written records 725 11% 136 17% 212 12% 154 10% 95 7% 128 11% 
Does not find data useful 682 10% 60 8% 146 8% 200 14% 154 12% 122 11% 
Uses a mobile medical application to assist 
with diabetes care – N(%) 1799 16% 303 23% 566 18% 425 17% 334 16% 171 9% 
Tasks performed using mobile medical 
applicationd – N(%) 
            
View glucose meter data 352 20% 42 14% 116 20% 84 20% 62 19% 48 28% 
View CGM data 1298 72% 248 82% 416 73% 280 66% 243 73% 111 65% 
View insulin pump data 175 10% 31 10% 56 10% 30 7% 26 8% 32 19% 
Manage patterns and adjust insulin 400 22% 67 22% 103 18% 97 23% 83 25% 50 29% 
Share results with healthcare provider 409 23% 66 22% 108 19% 82 19% 87 26% 66 39% 
Share results with family members 485 27% 124 41% 193 34% 94 22% 43 13% 31 18% 
Record foods 226 13% 19 6% 49 9% 84 20% 54 16% 20 12% 
Track exercise 207 12% 9 3% 34 6% 70 16% 68 20% 26 15% 
Page 35 of 37 
 
Diabetes mobile medical applications 
usedd – N(%) 
            
Dexcom Share 1218 68% 239 79% 408 72% 267 63% 211 63% 93 54% 
Medtronic Connect 135 8% 19 6% 33 6% 25 6% 36 11% 22 13% 
Glooko 73 4% 13 4% 25 4% 13 3% 14 4% 8 5% 
Tidepool 44 2% 2 <1% 5 <1% 10 2% 18 5% 9 5% 
MySugr 91 5% 8 3% 27 5% 37 9% 16 5% 3 2% 
Hypoglycemia awareness             
Awareness of beginning to experience low 
blood sugar (0=Never aware and 5 = 
Always aware) – median (IQR) 
4 (3,5) 4 (3,4) 4 (4,5) 4 (4,5) 4 (3,5) 4 (3,5) 
Level of blood sugar before feel symptoms 
– N(%) 
            
At least 3·9 mmol/L (70 mg/dL) 4637 42% 534 41% 1628 51% 1271 52% 712 33% 492 25% 
3·3-3·8 mmol/L (60-69 mg/dL) 3670 33% 439 33% 1009 32% 835 34% 791 37% 596 30% 
2·8-3·3 mmol/L (50-59 mg/dL) 1788 16% 225 17% 399 13% 264 11% 429 20% 470 24% 
2·2-2·7 mmol/L (40-49 mg/dL) 538 5% 69 5% 80 3% 45 2% 121 6% 223 11% 
<2·2 mmol/L (<40 mg/dL) 320 3% 33 3% 51 2% 22 <1% 69 3% 145 7% 
Never feel symptoms 108 <1% 13 <1% 16 <1% 8 <1% 21 <1% 50 3% 
aN=7568 participants reported insulin pump use; N=3480 reported multiple daily injection use 
bN=3830 participants reported using a CGM; N=223 reported using a Medtronic 530G pump/CGM 
cN=297 participants reported not using a blood glucose meter (N=246 non-CGM users  | N=51 CGM users) 
dProportions of each row assessed individually (represent row percentages) 
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Supplemental Table S5. HbA1c by Participant Characteristics: 2016-2018 
 HbA1c (Mean ± StD)*  
 1 - 5       
yrs old 
6 - 12  
yrs old 
13 - 17  
yrs old 
18 - 25  
yrs old 
26 - 49  
yrs old 
≥50     
 yrs old 
 
 N= 415 N=3688 N= 6675 N= 4535 N= 3939 N=3445 P-valuea 
Overall 66±13.1 
8.2±1.2 
69±15.3 
8.5±1.4 
77±20.8 
9.2±1.9 
74±20.8 
8.9±1.9 
62±16.4 
7.8±1.5 
61±13.1 
7.7±1.2 
<0.001 
Race/Ethnicity       <0.001 
     White Non-Hispanic 64±12 
8.0±1.1 
68±14.2 
8.4±1.3 
75±19.7 
9.0±1.8 
72±19.7 
8.7±1.8 
61±14.2 
7.7±1.3 
60±13.1 
7.6±1.2 
 
     Black Non-Hispanic 75±16.4 
9.0±1.5 
81±18.6 
9.6±1.7 
92±24 
10.6±2.2 
89±25.1 
10.3±2.3 
77±24 
9.2±2.2 
72±17.5 
8.7±1.6 
 
     Hispanic or Latino 68±16.4 
8.4±1.5 
72±15.3 
8.7±1.4 
80±21.9 
9.5±2.0 
79±23 
9.4±2.1 
65±15.3 
8.1±1.4 
62±12 
7.8±1.1 
 
     Other 69±14.2 
8.5±1.3 
73±16.4 
8.8±1.5 
80±21.9 
9.5±2.0 
76±21.9 
9.1±2.0 
64±18.6 
8.0±1.7 
63±14.2 
7.9±1.3 
 
Annual Household Income       <0.001 
     < $50,000 72±131 
8.7±1.2 
75±16.4 
9.0±1.5 
85±23 
9.9±2.1 
80±23 
9.5±2.1 
66±17.5 
8.2±1.6 
64±14.2 
8.0±1.3 
 
     $50,000 - <$75,000 64±12 
8.0±1.1 
70±14.2 
8.6±1.3 
77±19.2 
9.2±1.8 
74±19.2 
8.9±1.8 
62±14.2 
7.8±1.3 
61±13.1 
7.7±1.2 
 
     ≥$75,000 61±10.9 
7.7±1.0 
65±12 
8.1±1.1 
73±18.6 
8.8±1.7 
70±18.6 
8.6±1.7 
58±13.1 
7.5±1.2 
58±10.9 
7.5±1.0 
 
Pump use       <0.001 
     Pump 63±12 
7.9±1.1 
67±13.1 
8.3±1.2 
74±18.6 
8.9±1.7 
70±17.5 
8.6±1.6 
61±13.1 
7.7±1.2 
60±12 
7.6±1.1 
 
     Multiple daily injections 69±14.2 
8.5±1.3 
74±16.4 
8.9±1.5 
83±23 
9.7±2.1 
78±24 
9.3±2.2 
66±18.6 
8.2±1.7 
62±15.3 
7.8±1.4 
 
CGM use       <0.001 
     CGM user 61±10.9 
7.7±1.0 
64±10.9 
8.0±1.0 
69±16.4 
8.5±1.5 
67±16.4 
8.3±1.5 
57±10.9 
7.4±1.0 
57±10.9 
7.4±1.0 
 
     Non-CGM user 72±13.1 
8.7±1.2 
73±15.3 
8.8±1.4 
80±21.9 
9.5±2.0 
76±21.9 
9.1±2.0 
65±17.5 
8.1±1.6 
62±14.2 
7.8±1.3 
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Self-Monitoring of Blood Glucoseb       <0.001 
0-3 times per day 81±17.5 
9.6±1.6 
85±20.8 
9.9±1.9 
88±21.9 
10.2±2.0 
81±21.9 
9.6±2.0 
70±19.7 
8.6±1.8 
68±16.4 
8.4±1.5 
 
4-6 times per day 72±13.1 
8.7±1.2 
73±14.2 
8.8±1.3 
74±17.5 
8.9±1.6 
67±16.4 
8.3±1.5 
62±13.1 
7.8±1.2 
61±12 
7.7±1.1 
 
6-9  times per day 65±10.9 
8.1±1.0 
68±12 
8.4±1.1 
66±15.3 
8.2±1.4 
63±16.4 
7.9±1.5 
56±10.9 
7.3±1.0 
56±9.8 
7.3±0.9 
 
≥ 10 times per day 67±8.7 
8.3±0.8 
64±9.8 
8.0±0.9 
63±9.8 
7.9±0.9 
63±17.5 
7.9±1.6 
55±12 
7.2±1.1 
52±8.7 
6.9±0.8 
 
 
*In each cell, HbA1c is expressed as mmol/mol on top and % on bottom. 
 
aP-value from multivariable linear regression model; annual income was included as an ordinal factor and self-monitoring of blood glucose was 
included as a continuous factor in the model 
bSelf-monitoring of blood glucose assessed in non-CGM users 
